Holen Sie sich die Stockscreener-App
243.01
0.46%
1.12
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$241.89
Offen:
$243
24-Stunden-Volumen:
292.66K
Relative Volume:
0.27
Marktkapitalisierung:
$26.82B
Einnahmen:
$11.28B
Nettoeinkommen (Verlust:
$1.07B
KGV:
26.81
EPS:
9.0657
Netto-Cashflow:
$1.33B
1W Leistung:
+3.45%
1M Leistung:
+2.83%
6M Leistung:
+23.81%
1J Leistung:
+33.39%
1-Tages-Spanne:
$241.12
$244.22
1-Wochen-Bereich:
$223.50
$246.00
52-Wochen-Spanne:
$171.18
$248.84
Quest Diagnostics Inc Stock (DGX) Company Profile
Firmenname
Quest Diagnostics Inc
Sektor
Branche
Telefon
(973) 520-2700
Adresse
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, NTRA, A, IQV
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
243.01 | 26.82B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
677.68 | 250.57B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
232.06 | 163.13B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
405.04 | 58.38B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
175.37 | 49.44B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
274.98 | 45.26B | 16.63B | 1.39B | 2.12B | 8.0674 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Eingeleitet | Redburn Atlantic | Buy |
| 2025-03-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-01-06 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Fortgesetzt | Jefferies | Buy |
| 2024-10-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Fortgesetzt | Evercore ISI | In-line |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-02-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2023-12-12 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-29 | Eingeleitet | Piper Sandler | Neutral |
| 2023-05-02 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-01-23 | Eingeleitet | Evercore ISI | In-line |
| 2022-11-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-08-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-02-23 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-02 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-28 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Hochstufung | UBS | Neutral → Buy |
| 2021-03-12 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Hochstufung | Argus | Hold → Buy |
| 2020-07-29 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-06-09 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-04-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Herabstufung | Goldman | Neutral → Sell |
| 2019-04-02 | Hochstufung | Jefferies | Hold → Buy |
| 2019-03-18 | Fortgesetzt | Credit Suisse | Neutral |
| 2019-01-31 | Herabstufung | Argus | Buy → Hold |
| 2019-01-17 | Eingeleitet | UBS | Neutral |
| 2019-01-03 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Herabstufung | Goldman | Buy → Neutral |
Alle ansehen
Quest Diagnostics Inc Aktie (DGX) Neueste Nachrichten
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term - Zacks Investment Research
DGX Q3 Earnings & Revenues Beat, '26 View Raised, Stock Down in Pre-Market - Zacks Investment Research
Quest Diagnostics (DGX) Q3 Earnings and Revenues Beat Estimates - Zacks Investment Research
Quest Diagnostics (DGX): Is Rapid Test Growth Translating Into Better Customer Economics? - Yahoo Finance
Waters, Quest Diagnostics Collaborate to Expand Access to At-Home HPV Screening for Cervical Cancer - marketscreener.com
Quest Diagnostics Inc expected to post earnings of $2.86 a shareEarnings Preview - TradingView
Quest Diagnostics, Waters plan at-home HPV access in 2027 | DGX Stock News - Stock Titan
A new at-home HPV test kit is going national through Quest Diagnostics - Fast Company
Quest Diagnostics Slides as Investors Weigh Medicare Lab Payment Cut Risk - Quiver Quantitative
UBS Raises Quest Diagnostics Price Target to $250 From $245, Maintains Neutral Rating - marketscreener.com
Current guidelines may miss half of people with a hormone disorder tied to high blood pressure. - Stock Titan
DGX4807226 Bond Profile: Coupon and Redemption - TradingView
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors - MarketWatch
Quest Diagnostics Incorporated (DGX) Options ChainYahoo Finance - Yahoo! Finance Canada
Quest Diagnostics Incorporated (DGX) Options ChainYahoo Finance - Yahoo! Finance Canada
Quest Diagnostics Incorporated (DGX) Options ChainYahoo Finance - Yahoo! Finance Canada
Quest Diagnostics Incorporated (DGX) Stock forecasts - Yahoo Finance UK
Quest Diagnostics shares may shift 4.4% on Oct. 22 earnings - Investing.com
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo Finance
Quest Continues to Enjoy a Narrow Moat Thanks to Its Status as Low-Cost Producer - Morningstar
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Incorporated (DGX) Stock Forecasts - Yahoo! Finance Canada
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - Zacks Investment Research
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - TradingView
Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings - Yahoo Finance
Quest Diagnostics (NYSE:DGX): A Dividend Quality Pick for Income Investors - ChartMill
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Leerink Partners Adjusts Quest Diagnostics Price Target to $265 From $254 - www.marketscreener.com
Quest Diagnostics Incorporated (DGX) options chain - Yahoo Finance UK
Quest Diagnostics (DGX) Announces Executive Leadership Transitio - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Catherine T. Doherty to Transition to EVP at Quest Diagnostics, Retirement Set for July 2027 - TradingView
Barclays Adjusts Price Target on Quest Diagnostics to $260 From $250, Keeps Overweight Rating - marketscreener.com
Evercore ISI Adjusts Price Target on Quest Diagnostics to $235 From $240, Keeps In Line Rating - www.marketscreener.com
Quest Diagnostics Inc's Dividend Analysis - Yahoo Finance
Quest Diagnostics (NYSE:DGX) Rides Steady Testing Demand - Kalkine Media
Quest Diagnostics’ Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in Focus - Zacks Investment Research
DGX5874579 Bond Profile: Coupon and Redemption - TradingView
Three Days Left To Buy Quest Diagnostics Incorporated (NYSE:DGX) Before The Ex-Dividend Date - Moomoo
Quest Diagnostics (NYSE:DGX) Breakout Setup Backed by Technical Rating 7 and Setup Rating 8 - ChartMill
Quest Diagnostics (DGX) Highlights Haystack MRD Test Accuracy in Colorectal Cancer Trials - GuruFocus
Quest Diagnostics Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - TradingView
Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally? - Yahoo Finance
Global Paternity & Relationship Testing Services Market Set for Growth Through 2030 as DNA Testing Demand Expands Across Applications and Product Segments - GlobeNewswire Inc.
Quest Diagnostics (DGX) Could Be 5% Below Fair Value After Apple Health Launch - Yahoo Finance
Quest Diagnostics shows growth potential despite Medicare uncertainties, driven by testing demand and acquisitions. - Pluang
Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds - Seeking Alpha
Finanzdaten der Quest Diagnostics Inc-Aktie (DGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Quest Diagnostics Inc-Aktie (DGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Davis J. E. | Officer |
Sep 01 '26 |
Proposed Sale |
242.72 |
10,000 |
2,427,200 |
0 |
| PREVOZNIK MICHAEL E | SVP & General Counsel |
Aug 28 '26 |
Sale |
243.11 |
22,677 |
5,513,083 |
37,557 |
| PREVOZNIK MICHAEL E | SVP & General Counsel |
Aug 28 '26 |
Option Exercise |
112.17 |
22,677 |
2,543,679 |
60,234 |
| PREVOZNIK MICHAEL E | Officer |
Aug 28 '26 |
Proposed Sale |
243.11 |
22,677 |
5,513,082 |
0 |
| DELANEY MARK E | Officer |
Jul 28 '26 |
Proposed Sale |
235.18 |
1,600 |
376,288 |
0 |
| DELANEY MARK E | SVP & Chief Commercial Officer |
Jul 28 '26 |
Sale |
235.18 |
1,600 |
376,288 |
10,335 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Jun 04 '26 |
Option Exercise |
124.22 |
8,147 |
1,012,000 |
21,657 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions |
Jun 04 '26 |
Sale |
200.00 |
8,147 |
1,629,400 |
13,510 |
| KUPPUSAMY KARTHIK | Officer |
Jun 04 '26 |
Proposed Sale |
200.00 |
8,147 |
1,629,400 |
0 |
| Davis J. E. | CEO and President |
Jun 01 '26 |
Sale |
194.14 |
10,000 |
1,941,400 |
132,423 |
0.28%
3.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):